In vitro studies of 223Ra- and 225Ac-labelled α-zirconium phosphate as potential carrier for alpha targeted therapy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F23%3A00363447" target="_blank" >RIV/68407700:21340/23:00363447 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1007/s10967-022-08742-y" target="_blank" >https://doi.org/10.1007/s10967-022-08742-y</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10967-022-08742-y" target="_blank" >10.1007/s10967-022-08742-y</a>

Result language
angličtina
Original language name
In vitro studies of 223Ra- and 225Ac-labelled α-zirconium phosphate as potential carrier for alpha targeted therapy
Original language description
In this study suitability of α-ZrP nanoparticles as a 223Ra and 225Ac carriers for TAT was investigated. The yields of radiolabelling were higher than 98% in both cases. Subsequently, in vitro stability studies were carried out in various biological matrices during 48 h period. Measurements of released radioactivity showed the highest stability in saline. Released activity of 223Ra, 225Ac and their daughter radionuclides was around 0.5%. On the other hand, the lowest stability was shown in plasma and serum. Released activity for 223Ra, 225Ac and their progeny atoms was from 15 to 32%.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10402 - Inorganic and nuclear chemistry

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)